Tempest Therapeutics holds annual stockholder meeting
TPST•Tempest Therapeutics shareholders approved a potential issuance of 20% or more of outstanding common stock to Lincoln Park on November 9, 2026, and authorized shares underlying Series C and Series D warrants and placement agent warrants.
1. Shareholder approvals
Shareholders approved the potential issuance to Lincoln Park and authorized up to 3,105,591 common shares underlying each of the outstanding Series C and Series D warrants under the PIPE proposal. The approval also covered up to 217,391 shares underlying placement agent warrants issued to H.C. Wainwright designees. John David Yee and William Drake Richey were elected Class II directors, and Ernst & Young was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
